XOMA CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.4 USD | +0.16% |
|
-1.57% | +35.57% |
| Apr. 03 | XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. | CI |
| Mar. 08 | XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 14.1M | Sales 2025 * | 20.65M | Capitalization | 295M |
|---|---|---|---|---|---|
| Net income 2024 * | -24M | Net income 2025 * | -20M | EV / Sales 2024 * | 20.9 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-14.9
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.09% | ||
| 1 week | +3.13% | ||
| Current month | +5.45% | ||
| 1 month | +5.67% | ||
| 3 months | +23.05% | ||
| 6 months | +44.25% | ||
| Current year | +37.08% |
1 week
25.20
26.79
1 month
23.0027.00
Current year
18.5727.00
1 year
13.4827.00
3 years
13.4839.49
5 years
11.5846.32
10 years
3.96119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 27 M€ | -5.44% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 25.08 | -1.10% | 2 702 |
| 24-04-25 | 25.36 | -1.09% | 6,783 |
| 24-04-24 | 25.64 | -1.72% | 8,219 |
| 24-04-23 | 26.09 | +1.05% | 11,780 |
| 24-04-22 | 25.82 | +1.33% | 7,314 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
25.36
USD
Average target price
74
USD
Spread / Average Target
+191.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.08% | 295M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.73% | 22.02B | |
| -17.84% | 20.9B | |
| -9.03% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- XOMA Stock
